Insider Buying: Ascendis Pharma A/S (NASDAQ:ASND) CFO Buys $21,900.00 in Stock

Ascendis Pharma A/S (NASDAQ:ASND) CFO Scott Thomas Smith bought 100 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were acquired at an average price of $219.00 per share, with a total value of $21,900.00. Following the acquisition, the chief financial officer owned 4,367 shares of the company’s stock, valued at $956,373. This represents a 2.34% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Ascendis Pharma A/S Price Performance

Shares of Ascendis Pharma A/S stock opened at $218.84 on Friday. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79. The company has a market cap of $13.65 billion, a PE ratio of 25.24 and a beta of 0.39. The business has a 50 day moving average of $233.36 and a 200 day moving average of $223.69. Ascendis Pharma A/S has a 52 week low of $160.86 and a 52 week high of $250.74.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.11. The business had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million. As a group, equities research analysts forecast that Ascendis Pharma A/S will post 12.85 earnings per share for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its position in shares of Ascendis Pharma A/S by 4.0% during the second quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock valued at $249,000 after buying an additional 55 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Ascendis Pharma A/S by 1.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,081 shares of the biotechnology company’s stock valued at $1,209,000 after buying an additional 58 shares during the last quarter. Certuity LLC boosted its position in shares of Ascendis Pharma A/S by 5.7% during the fourth quarter. Certuity LLC now owns 1,170 shares of the biotechnology company’s stock valued at $249,000 after buying an additional 63 shares during the last quarter. Personal CFO Solutions LLC boosted its position in shares of Ascendis Pharma A/S by 4.4% during the first quarter. Personal CFO Solutions LLC now owns 1,519 shares of the biotechnology company’s stock valued at $347,000 after buying an additional 64 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Ascendis Pharma A/S by 34.0% during the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 69 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts recently commented on ASND shares. Morgan Stanley restated an “overweight” rating and set a $256.00 target price on shares of Ascendis Pharma A/S in a report on Thursday, February 12th. The Goldman Sachs Group reiterated a “buy” rating and issued a $255.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Royal Bank Of Canada increased their price objective on Ascendis Pharma A/S from $250.00 to $275.00 and gave the stock an “outperform” rating in a report on Monday, March 2nd. Wall Street Zen upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Barclays increased their price objective on Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Ascendis Pharma A/S has an average rating of “Buy” and an average target price of $295.39.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.